RAMIFENTANYL
Uterine Myoma
Chosun University HospitalSmall moleculeN/ADormant
D
30/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 15/ 100
- Competitive Position
- 95/ 100
Competitive context
1 Active assets in the Uterine Myoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Rocuronium Stony Brook University | Phase 4 | BB |
(±)-1-BUTYL-2',6'-PIPECOLOXYLIDIDE MONOHYDROCHLORIDE University of California, Irvine | Phase 3 | B |
Cyclobenzaprine Christiana Care Health Services | Phase 4 | B |
Hcg Lebanese University | Phase 1/2 | CCC |
Indocyanine Green Chen Chunlin | Early Phase 1 | CC |
Desflurane Chosun University Hospital | N/A | D |
lfa102 Novartis Pharmaceuticals | Phase 1 | NR |
Same molecule, other indications
RAMIFENTANYL is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →